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Summary
Objectives: Low levels of adiponectin, an adipocytokine with anti-diabetic and anti-
atherogenic properties, are associated with increased risk of future myocardial
infarction in men. Previous studies have demonstrated that cigarette smoking is
involved in the development of insulin resistance, and current smokers have been
shown to have reduced plasma adiponectin levels. However, the inﬂuence of smok-
ing cessation on adiponectin levels remains unknown. We sought to assess whether
smoking cessation is associated with increased plasma adiponectin levels in men.
Methods: The study includes 72men (47 non-smokers and 25 current smokers at base-
line) with stable angina pectoris who underwent percutaneous coronary intervention
and follow-up coronary angiography 6 months later. During the 6-month follow-up
period, all 47 non-smokers remained non-smokers, while 15 men of the 25 baseline
current smokers successfully quit smoking. We evaluated plasma adiponectin levels
at coronary intervention and 6 months later.
Results: Plasma adiponectin levels at coronary intervention were comparable to
those after 6 months in non-smokers (4.22 [3.15—6.43] vs. 4.58 [3.03—6.26]g/mL,
P = 0.124) and in persistent smokers (4.77 [4.25—10.53] vs. 5.16 [4.11—8.10]g/mL,
P = 0.721). Meanwhile, an increase in adiponectin level was observed in patients who
quit smoking for 6 months (4.24 [3.30—5.70] vs. 5.50 [4.03—8.00]g/mL, P = 0.002).
∗ Corresponding author. Tel.: +81 96 373 5175; fax: +81 96 362 3256.
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Univariate analysis revealed that the percent increase in adiponectin levels corre-
lated positively with smoking cessation (P = 0.003) and negatively with additional use
of -blockers (P = 0.049). In addition, increases in adiponectin levels were closely
associated with increase in high-density lipoprotein cholesterol (P = 0.148), decrease
in triglycerides (P = 0.140), and additional use of renin—angiotensin system inhibitors
(P = 0.069). Multivariate analysis demonstrated that smoking cessation was an inde-
pendent determinant of the increase in adiponectin (P = 0.036).
Conclusions: Smoking cessation is associated with increased plasma adiponectin levels
in men with stable angina, suggesting that the signiﬁcance of smoking cessation may
be partly explained by the increase in adiponectin level.
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Introduction
The adipocyte-derived plasma protein adiponectin
is closely associated with insulin sensitivity, and
has been identiﬁed as a marker of the metabolic
syndrome [1]. Adiponectin has anti-atherogenic
properties [1], and low levels of adiponectin are
known to be associated with coronary artery dis-
ease [2] and increased risk of future myocardial
infarction (MI) [3]. We have previously reported
that plasma adiponectin levels are inversely asso-
ciated with atherosclerotic burden [4], and that
low levels of adiponectin are associated with angio-
graphic coronary lesion complexity, suggestive of
coronary plaque instability [5]. Thus, a decrease
in adiponectin levels may contribute to the devel-
opment of atherosclerotic disease including acute
coronary syndromes, as well as metabolic syn-
drome.
Cigarette smoking is a major risk factor for
atherosclerotic disease, and cessation of smoking is
an important preventive strategy against cardiovas-
cular disease (CVD). Previous studies revealed that
cigarette smoking increases inﬂammation, throm-
bosis, and oxidation of low-density lipoprotein
cholesterol [6,7]. In addition, cigarette smoking
is known to be associated with insulin resis-
tance [8], and a recent observation in adolescents
demonstrated a signiﬁcant dose—response rela-
tionship between tobacco smoke exposure and
the incidence of metabolic syndrome [9]. Sev-
eral cross-sectional studies indicated that smoking
habit may be associated with low plasma levels of
adiponectin [10,11], suggesting one possible mech-
anism through which cigarette smoking contributes
to the development of atherosclerotic disease.
However, the inﬂuence of smoking cessation on
plasma adiponectin levels remains to be eluci-
dated.The hypothesis tested in the present study
was that cessation of smoking results in increase
in plasma adiponectin levels. To investigate this
hypothesis, we measured plasma adiponectin lev-
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ls in men with stable angina pectoris at coronary
ntervention and 6 months later.
ethods
tudy population
he study subjects were 72 men with stable effort
ngina who underwent percutaneous coronary
ntervention and follow-up coronary angiography
months later at Kumamoto University Hospi-
al. Patients with acute coronary syndromes were
xcluded from the study, because they are known
o have lower levels of plasma adiponectin than
atients with stable coronary artery disease, as
e have reported previously [5]. We also excluded
atients with malignant disease, infectious dis-
ase, chronic inﬂammatory disease, autoimmune
isease, and advanced renal disease (serum crea-
inine level >2.5mg/dL). None of the patients was
aking any type of thiazolidinedione, which is an
nsulin-sensitizing agent known to increase plasma
oncentrations of adiponectin [12]. In addition,
one of the patients was using any anti-smoking
gents such as nicotine patches or varenicline.
he group included 47 non-smokers and 25 current
mokers at baseline. During the 6-month follow-up
eriod, all 47 non-smokers remained non-smokers,
hile 15 men of the 25 baseline current smok-
rs successfully quit smoking. Written informed
onsent was obtained from each patient before par-
icipation in the study. The study was performed in
ccordance with the ethics principles in the Dec-
aration of Helsinki and the study protocol was
pproved by the ethics committee of our institu-lood sampling and measurement of plasma
diponectin
enous blood samples were obtained in the early
orning from all subjects after a 12-h fast. Plasma
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Table 1 Baseline clinical characteristics of 72 men with stable effort angina.
Non-smokers (n = 47) Persistent smokers (n = 10) Quitters (n = 15) P
Age (years) 68.5± 9.3 66.5± 7.2 68.3± 7.0 0.794
BMI (kg/m2) 24.4± 2.7 24.1± 3.7 23.2± 3.0 0.395
Hypertension 39 (83%) 6 (60%) 12 (80%) 0.266
Diabetes mellitus 21 (45%) 5 (50%) 4 (27%) 0.397
Fasting glucose (mg/dL) 108.1± 31.9 105.3± 23.6 100.8± 27.8 0.712
Hemoglobin A1c (%) 6.2± 1.2 5.7± 0.6 5.6± 0.9 0.181
Total cholesterol (mg/dL) 200.0± 40.0 187.0± 29.3 188.6± 42.7 0.470
HDL cholesterol (mg/dL) 47.3± 11.2 42.6± 15.0 50.5± 27.3 0.500
LDL cholesterol (mg/dL) 133.4± 39.4 120.5± 18.4 126.5± 32.3 0.534
Triglycerides (mg/dL) 131.0 (95.3—153.0) 122.5 (97.0—142.0) 121.0 (75.8—144.8) 0.740
Creatinine (mg/dL) 0.86± 0.37 0.93± 0.31 1.01± 0.40 0.239
CRP (mg/dL) 0.27 (0.05—0.56) 0.16 (0.10—0.22) 0.23 (0.05—0.43) 0.881
Adiponectin (g/mL) 4.22 (3.15—6.43) 4.77 (4.25—10.53) 4.24 (3.30—5.70) 0.343
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HDL = high-density lipoprotein; LDL = low-density lipoprotein.
amples were immediately stored at −80 ◦C for
ubsequent assay of adiponectin levels by enzyme-
inked immunosorbent assay (adiponectin ELISA kit,
tsuka Pharmaceutical, Tokyo, Japan) as described
reviously [4,13]. We measured plasma adiponectin
evels at coronary intervention and 6 months later.
tatistical analysisesults for normally distributed continuous vari-
bles are expressed as mean values± S.D., and
hose for continuous variables with skewed distribu-
ions are expressed as median values (interquartile
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igure 1 Changes in plasma adiponectin levels in non-smo
n = 15). In box-and-whisker plots, the lines within the boxes
f the boxes represent the 75th and 25th percentiles, respec
epresent the 90th and 10th percentiles, respectively.ge) or n (%). BMI = body mass index; CRP =C-reactive protein;
anges). Differences between continuous variables
ere analyzed by one-way analysis of variance fol-
owed by Scheffe’s test, and the Kruskal—Wallis
est, as appropriate. Categorical variables are
resented by frequency counts, and intergroup
omparisons were analyzed by the 2-test. Changes
n normally distributed variables were assessed
sing paired t-test, and those with skewed distri-
ution were assessed by Wilcoxon signed rank test.
orrelations between percent change in plasma
diponectin levels and those at baseline variables
ere ﬁrst assessed by Spearman two-way test.
ultivariate analysis was performed to assess the
kers (n = 47), persistent smokers (n = 10), and quitters
represent median values; the upper and lower borders
tively; and the upper and lower bars outside the boxes
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Table 2 Comparison of variables at baseline and after 6 months in baseline current smokers.
Persistent smokers (n = 10) Quitters (n = 15)
Baseline After 6 months P Baseline After 6 months P
Body weight (kg) 64.4± 11.5 63.9± 7.4 0.803 61.4± 8.6 60.5± 10.7 0.558
BMI (kg/m2) 24.1± 3.7 24.0± 2.5 0.850 23.2± 3.0 23.3± 3.3 0.814
Fasting glucose (mg/dL) 105.3± 23.6 102.4± 22.0 0.602 100.8± 27.8 97.5± 15.4 0.503
Hemoglobin A1c (%) 5.7± 0.6 5.9± 0.6 0.573 5.6± 0.9 5.6± 0.5 0.878
Total cholesterol (mg/dL) 187.0± 29.3 178.0± 20.9 0.301 188.6± 42.7 169.4± 29.9 0.108
HDL cholesterol (mg/dL) 42.6± 15.0 43.3± 9.5 0.839 50.5± 27.3 47.9± 8.4 0.498
LDL cholesterol (mg/dL) 120.5± 18.4 120.3± 20.5 0.975 126.5± 32.3 107.4± 26.2 0.014
Triglycerides (mg/dL) 122.5 (97.0—142.0) 126.0 (108.0—158.0) 0.767 121.0 (75.8—144.8) 110.5 (90.0—140.0) 0.851
CRP (mg/dL) 0.16 (0.10—0.22) 0.19 (0.08—0.50) 0.213 0.23 (0.05—0.43) 0.13 (0.07—0.27) 0.168
Adiponectin (g/mL) 4.77 (4.25—10.53) 5.16 (4.11—8.10) 0.721 4.24 (3.30—5.70) 5.50 (4.03—8.00) 0.002
Medication (%)
Aspirin 80 100 73 100
-Blockers 0 40 20 33
Calcium antagonists 70 80 73 73
ACE inhibitors/ARBs 30 40 40 67
Statins 0 20 27 53
Nitrates 20 30 53 40
ACE = angiotensin converting enzyme; ARBs = angiotensin receptor blockers; other abbreviations as in Table 1.
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Table 3 Correlation between changes in plasma adiponectin levels and changes in baseline variables.
Univariate Multivariate
r-Value P B (95% CI) ˇ P
% Body weight −0.106 0.603
% BMI 0.017 0.932
% Fasting glucose 0.192 0.347
% Hemoglobin A1c −0.121 0.552
% Total cholesterol 0.116 0.579
% HDL cholesterol 0.302 0.148 0.754 (−0.414 to 1.922) 0.342 0.192
% LDL cholesterol 0.052 0.802
% Triglycerides −0.308 0.140 −0.093 (−0.739 to 0.553) −0.073 0.765
% CRP −0.079 0.719
Smoking cessation 0.611 0.003 0.490 (0.035 to 0.945) 0.477 0.036
Additional medications
Aspirin 0.195 0.340
-Blockers −0.403 0.049 0.031 (−0.544 to 0.605) 0.026 0.912
Calcium antagonists 0.041 0.841
ACE inhibitors/ARBs 0.371 0.069 0.208 (−0.272 to 0.687) 0.177 0.375
Statins −0.026 0.899
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Abbreviations as in Tables 1 and 2. B indicates increment of
variable; ˇ value corresponds to the standardized multiple reg
ndependent determinant of percent increase in
diponectin levels during the 6-month follow-up
eriod, and all factors with P < 0.20 based on the
esults of univariate analysis were entered into
his multivariate model. Statistical signiﬁcance was
eﬁned as P < 0.05. All analyses were performed
sing Stat View-V software (SAS Institute Inc., Cary,
C, USA).
esults
here were no signiﬁcant differences in baseline
ariables between non-smokers (n = 47), persistent
mokers (n = 10), and quitters (n = 15) (Table 1).
lasma adiponectin levels at coronary interven-
ion were comparable to those measured 6
onths later in non-smokers (4.22 [3.15—6.43]
s. 4.58 [3.03—6.26]g/mL, P = 0.124) and in
ersistent smokers (4.77 [4.25—10.53] vs. 5.16
4.11—8.10]g/mL, P = 0.721) (Fig. 1). In con-
rast, an increase in adiponectin level was
bserved in quitters (4.24 [3.30—5.70] vs. 5.50
4.03—8.00]g/mL, P = 0.002) (Fig. 1).
During the 6-month follow-up period, persis-
ent smokers and quitters did not show signiﬁcant
hanges in various clinical variables such as body
eight, glucose and lipid proﬁles, and C-reactive
rotein levels, except that a decrease in low-
ensity lipoprotein cholesterol level was observed
n quitters (Table 2). The baseline medications and
hose after 6 months are shown in Table 2.
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kplasma adiponectin levels for every unit of the independent
on coefﬁcient.
We assessed the independent determinants of
he increase in plasma adiponectin levels among
aseline current smokers (Table 3). Univariate
nalysis revealed that the percent increase in
lasma adiponectin levels correlated positively
ith smoking cessation (P = 0.003) and negatively
ith additional use of -blockers (P = 0.049).
n addition, the percent increase in plasma
diponectin level closely correlated positively
ith percent increase in high-density lipoprotein
holesterol levels (P = 0.148) and additional use
f renin—angiotensin system inhibitors (P = 0.069),
nd negatively with percent increase in triglyc-
ride levels (P = 0.140), although the difference was
ot statistically signiﬁcant. A multivariate analysis
ncluding these variables demonstrated that smok-
ng cessation was a signiﬁcant and independent
eterminant of the increase in plasma adiponectin
evels (P = 0.036).
iscussion
n this study, we demonstrated that 6-month
moking cessation was signiﬁcantly and indepen-
ently associated with increased plasma levels of
diponectin in men with stable angina pectoris.
he present ﬁndings suggest that the signiﬁcance of
moking cessation may be, at least in part, demon-
trated by increase in plasma adiponectin, which is
nown as an anti-atherogenic adipocytokine.
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The adipocyte-derived plasma protein adipo-
nectin is associated with insulin sensitivity [1].
Moreover, adiponectin has direct anti-atherogenic
properties [1] and a fall in the concentration of this
molecule is known to be associated with coronary
artery disease [2], restenosis after percutaneous
coronary intervention [14], and future incidence
of MI [3]. Cigarette smoking is an established risk
factor for CVD, while it correlates with insulin resis-
tance and the development of metabolic syndrome
[8,9]. Cigarette smoking correlates with low plasma
adiponectin levels [10,11], however, there is no
information on the correlation between smoking
cessation and plasma adiponectin levels.
In the present study, we demonstrated that
smoking cessation was signiﬁcantly associated with
increased plasma adiponectin levels. Although the
precise mechanisms are unclear, previous studies
support the association between smoking habit and
reduced adiponectin levels. It has been demon-
strated that nicotine directly inhibits the mRNA
expression of adiponectin in adipocytes [11]. Smoke
exposure is known to increase gene expression of
tumor necrosis factor- [15], which is inversely
associated with adiponectin gene expression [16].
Furthermore, it is characteristic of adiponectin
to accumulate in injured vessel walls but not in
intact vascular walls [17,18], and it is possible that
endothelial cell injury caused by cigarette smok-
ing results in increased consumption of circulating
adiponectin.
Smoking can potentially contribute to the devel-
opment of insulin resistance and the metabolic
syndrome [8,9], therefore, its cessation could
improve insulin sensitivity. On the other hand,
smoking cessation sometimes leads to body weight
gain [19], which seems to result in deterioration of
insulin sensitivity. Weight gain after smoking ces-
sation is largely due to increased body fat, and
the mechanism of weight gain includes increased
energy intake, decreased physical activity, and
increased lipoprotein lipase activity [20—22]. How-
ever, despite weight gain after quitting smoking, it
was reported that the increase in the waist-to-hip
ratio in those who quit smoking was not as much as
expected, and conversely, people who re-started
smoking after quitting showed signiﬁcant increase
in waist-to-hip ratio in spite of reduction in their
body weight [23]. Thus, body fat changes caused
by cigarette smoking might differ between abdom-
inal adipose tissue and subcutaneous region (which
is represented by hip circumference), and this may
account for the apparently discrepant phenomenon
after smoking cessation. Indeed, improvement
in insulin sensitivity after quitting smoking has
been demonstrated regardless of weight gain [24].
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lthough body weight gain after smoking cessation
as not observed in our subjects, the increase in
diponectin levels after smoking cessation may be
n line with previous studies.
Smoking cessation is important especially with
egard to the prevention of CVD. Previous stud-
es showed that smoking cessation signiﬁcantly
educed the risk of acute MI and stroke [25], and
ad beneﬁcial effects on cardiovascular morbidity
nd mortality [26]. To our knowledge, the present
tudy represents the ﬁrst report demonstrating
hat smoking cessation is signiﬁcantly associated
ith a rise in plasma levels of adiponectin in men
ith stable angina. Given the signiﬁcant associa-
ion between low adiponectin levels and increased
isk of CVD, our results may support the clinical
mportance of smoking cessation in the prevention
f atherosclerotic disease and may help promote
moking cessation in society at large.
This study was limited by the small sample size as
ell as the speciﬁc study subjects who underwent
ercutaneous coronary intervention. Moreover, sev-
ral additional medications were used during the
ollow-up period, although the association between
moking cessation and increase in adiponectin
evels was independent of such additional medi-
ations. Previous studies have demonstrated that
enin—angiotensin system inhibitors increase adi-
onectin levels, and that high-density lipoprotein
holesterol and triglycerides levels correlate with
diponectin levels [27,28]. In this study, the per-
ent increase in plasma adiponectin level was
losely associated with these variables, although
he difference was not statistically signiﬁcant. Fur-
her studies in a larger number of subjects including
he general population are required to conﬁrm our
esults.
In conclusion, a 6-month smoking cessation
eriod was signiﬁcantly associated with increased
lasma adiponectin levels in men with stable angina
ectoris. Our results suggest that the signiﬁcance of
moking cessation may be in part demonstrated by
he increase in plasma adiponectin concentrations.
cknowledgments
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